AMI463 / Vall d’Hebron University Hospital, Amira Therapeutics - LARVOL DELTA

Amira Therapeutics’ Lead Compound AMI463 Demonstrates 60% Tumor Reduction in Preclinical Oral Study (Altamira Therap Press Release) - "In addition to the in vivo results, in vitro studies have shown that AMI463 exhibits strong synergistic activity when combined with standard chemotherapy treatments in relapsed rhabdomyosarcoma (RMS), supporting its potential as a novel therapeutic option in difficult-to-treat pediatric cancers."

Preclinical • Rhabdomyosarcoma